Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage TNBC By Ogkologos - November 21, 2024 939 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BELLINI study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Women in science: Cancer research pioneers – part 2 January 25, 2023 FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive... July 8, 2026 10 Ways the Inflation Reduction Act will Impact Cancer Care August 18, 2022 Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... June 24, 2024 Load more HOT NEWS ASCO 2023 roundup: Blood tests, drugs and exercise Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... The team of over 60 scientists investigating the age-old mystery of... EMA Recommends Granting a Marketing Authorisation for Capmatinib
